Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral …

C Pelaia, MT Busceti, A Vatrella, GF Rago… - Pulmonary …, 2019 - Elsevier
Benralizumab is a humanized monoclonal antibody which binds to the α subunit of the
interleukin-5 (IL-5) receptor and to the FcγRIIIa receptor expressed by natural killer cells …

Blood eosinophil cationic protein and eosinophil-derived neurotoxin are associated with different asthma expression and evolution in adults

V Granger, F Zerimech, J Arab, V Siroux, P De Nadai… - Thorax, 2022 - thorax.bmj.com
Background Eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) are
proteins released by activated eosinophils whose role in adult asthma remains unclear …

Switch from IL-5 to IL-5-receptor α antibody treatment in severe eosinophilic asthma

N Drick, K Milger, B Seeliger, J Fuge… - Journal of asthma …, 2020 - Taylor & Francis
Background Anti-IL-5 antibodies represent an established therapy for severe eosinophilic
asthma (SEA), but some patients show inadequate response. The objective of this study was …

[HTML][HTML] The contribution of oxidative stress and inflamm-aging in human and equine asthma

M Bullone, JP Lavoie - International journal of molecular sciences, 2017 - mdpi.com
Aging is associated with a dysregulation of the immune system, leading to a general pro-
inflammatory state of the organism, a process that has been named inflamm-aging …

Questions in mild asthma: an official American Thoracic Society research statement

A Mohan, NL Lugogo, NA Hanania… - American journal of …, 2023 - atsjournals.org
Background: Patients with mild asthma are believed to represent the majority of patients with
asthma. Disease-associated risks such as exacerbations, lung function decline, and death …

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

B Sposato, G Camiciottoli, E Bacci, M Scalese… - Pulmonary …, 2020 - Elsevier
Background Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic
asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We …

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre …

C Pelaia, MT Busceti, S Solinas, R Terracciano… - Pulmonary …, 2018 - Elsevier
Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is
nowadays available in many countries for add-on biological therapy of severe eosinophilic …

Use of biomarkers to identify phenotypes and endotypes of severe asthma

TF Carr, M Kraft - Annals of Allergy, Asthma & Immunology, 2018 - Elsevier
Objective Severe asthma can be classified into phenotypes and endotypes, which may
inform clinicians about inflammatory pathways leading to disease and ultimately guide …

The emerging role of type 2 inflammation in asthma

A Matucci, S Bormioli, F Nencini, E Maggi… - Expert review of …, 2021 - Taylor & Francis
Introduction: Bronchial asthma (BA) is a chronic airways inflammatory disease. Based on the
biological mechanisms that underline the disease, asthma has been classified as type 2 or …

[HTML][HTML] Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

A Menzies-Gow, ME Wechsler, CE Brightling - Respiratory research, 2020 - Springer
Despite treatment with standard-of-care medications, including currently available biologic
therapies, many patients with severe asthma have uncontrolled disease, which is associated …